Pneumonia and inflammatory diseases of the pulmonary system such as chronic obstructive pulmonary disease and asthma continue to cause significant morbidity and mortality globally. While the etiology of these diseases is highly different, they share a number of similarities in the underlying inflammatory processes driving disease pathology. Multiple recent studies have identified failures in efferocytosis—the phagocytic clearance of apoptotic cells—as a common driver of inflammation and tissue destruction in these diseases. Effective efferocytosis has been shown to be important for resolving inflammatory diseases of the lung and the subsequent restoration of normal lung function, while many pneumonia-causing pathogens manipulate the efferocytic system to enhance their growth and avoid immunity. Moreover, some treatments used to manage these patients, such as inhaled corticosteroids for chronic obstructive pulmonary disease and the prevalent use of statins for cardiovascular disease, have been found to beneficially alter efferocytic activity in these patients. In this review, we provide an overview of the efferocytic process and its role in the pathophysiology and resolution of pneumonia and other inflammatory diseases of the lungs, and discuss the utility of existing and emerging therapies for modulating efferocytosis as potential treatments for these diseases.

Renal transplantation is the preferred treatment for patients with end-stage renal disease. The current gold standard of kidney preservation for transplantation is static cold storage (SCS) at 4 °C. However, SCS contributes to renal ischemia-reperfusion injury (IRI), a pathological process that negatively impacts graft survival and function. Recent efforts to mitigate cold renal IRI involve preserving renal grafts at higher or subnormothermic temperatures. These temperatures may be beneficial in reducing the risk of cold renal IRI, while also maintaining active biological processes such as increasing the expression of mitochondrial protective metabolites. In this review, we discuss different preservation temperatures for renal transplantation and pharmacological supplementation of kidney preservation solutions with hydrogen sulfide to determine an optimal preservation temperature to mitigate cold renal IRI and enhance renal graft function and recipient survival.

Kidney transplantation is preferred for end-stage renal disease. The current gold standard for kidney preservation is static cold storage (SCS) at 4 °C. However, SCS contributes to renal graft damage through ischemia–reperfusion injury (IRI). We previously reported renal graft protection after SCS with a hydrogen sulfide donor, sodium thiosulfate (STS), at 4 °C. Therefore, this study aims to investigate whether SCS at 10 °C with STS and Hemopure (blood substitute), will provide similar protection. Using in vitro model of IRI, we subjected rat renal proximal tubular epithelial cells to hypoxia–reoxygenation for 24 h at 10 °C with or without STS and measured cell viability. In vivo, we preserved 36 donor kidneys of Lewis rats for 24 h in a preservation solution at 10 °C supplemented with STS, Hemopure, or both followed by transplantation. Tissue damage and recipient graft function parameters, including serum creatinine, blood urea nitrogen, urine osmolality, and glomerular filtration rate (GFR), were evaluated. STS-treated proximal tubular epithelial cells exhibited enhanced viability at 10 °C compared with untreated control cells (p < 0.05). Also, STS and Hemopure improved renal graft function compared with control grafts (p < 0.05) in the early time period after the transplant, but long-term function did not reach significance. Overall, renal graft preservation at 10 °C with STS and Hemopure supplementation has the potential to enhance graft function and reduce kidney damage, suggesting a novel approach to reducing IRI and post-transplant complications.

Using multiple imaging modalities while performing independent experiments in parallel can greatly enhance the throughput of microscopy-based research, but requires the provision of appropriate experimental conditions in a format that meets the optical requirements of the microscope. Although customized imaging chambers can meet these challenges, the difficulty of manufacturing custom chambers and the relatively high cost and design inflexibility of commercial chambers has limited the adoption of this approach. Herein, we demonstrate the use of 3D printing to produce inexpensive, customized, live-cell imaging chambers that are compatible with a range of imaging modalities, including super-resolution microscopy. In this approach, biocompatible plastics are used to print imaging chambers designed to meet the specific needs of an experiment, followed by adhesion of the printed chamber to a glass coverslip, producing a chamber that is impermeant to liquids and that supports the growth and imaging of cells over multiple days. This approach can also be used to produce moulds for casting microfluidic devices made of polydimethylsiloxane. The utility of these chambers is demonstrated using designs for multiplex microscopy, imaging under shear, chemotaxis, and general cellular imaging. Together, this approach represents an inexpensive yet highly customizable approach for producing imaging chambers that are compatible with modern microscopy techniques.

Background/Objectives: Radiomics-based machine learning models have demonstrated high accuracy in differentiating benign from malignant orbital masses, with early studies suggesting performance comparable to expert radiologists. However, translation into clinical practice remains limited due to dataset constraints, including retrospective study designs, single-center cohorts, and underrepresentation of diverse patient populations. This review aims to evaluate the current evidence supporting radiomics in orbital disease while critically examining barriers to generalizability and equity across ophthalmology, otolaryngology, and plastic surgery. Methods: A narrative literature review was conducted to assess radiomics applications in orbital oncology and reconstruction. Studies evaluating diagnostic accuracy, margin assessment, postoperative surveillance, and surgical planning across ophthalmology, head and neck surgery, and reconstructive surgery were analyzed, with particular attention paid to dataset composition, validation strategies, and imaging standardization. Results: Radiomics models demonstrated high diagnostic performance in differentiating orbital tumors, optimizing surgical planning, and aiding postoperative monitoring. However, most studies relied on small, homogeneous datasets lacking racial, ethnic, and pediatric representation. External validation was uncommon, and imaging heterogeneity limited reproducibility. These deficiencies restrict the clinical translation of radiomics and risk exacerbating healthcare disparities, particularly among underrepresented populations. Conclusions: Radiomics holds promise as a precision medicine tool for orbital diagnosis, surgical navigation, and postoperative care. Nevertheless, its clinical adoption is constrained by dataset bias, lack of standardization, and limited prospective validation. Future progress requires multi-institutional, demographically diverse datasets and standardized imaging protocols to ensure equitable and generalizable implementation across specialties.

Minimally invasive voice-preservation techniques, including microlaryngoscopy, phonosurgery, and office-based regenerative interventions, have revolutionized the management of benign and early-stage laryngeal disorders by minimizing fibrosis and preserving phonatory function. However, the long-term (>6 months) wound healing and extracellular matrix (ECM) remodeling dynamics that determine sustained vocal outcomes remain poorly understood, particularly among professional singers who experience high vibratory demand. Moreover, African American and minority singers continue to face significant barriers to specialty laryngology care, underrepresentation in research cohorts, and disparities in insurance coverage, creating inequities in both access and postoperative outcomes. This review synthesizes evidence on chronic wound healing and ECM remodeling following minimally invasive voice-preservation procedures, emphasizing histologic integration, molecular mediators of fibrosis, and correlations with objective (dysphonia severity index, vocal extent measure, and maximum phonation time) and subjective (voice handicap index, singing voice handicap index) recovery metrics. It also examines racial and socioeconomic inequities in laryngeal care among professional voice users. Our method for this research was to use PubMed, JStor, Web of Science, and Cochrane Library databases starting from 2000. The study will include randomized controlled trials and observational cohorts and case series with ten or more patients and previous systematic reviews that focus on wound healing and functional outcomes and access disparities. Two reviewers will conduct independent screening and data extraction, while thematic synthesis will be used to organize existing evidence and identify areas where more research is needed. Existing studies demonstrate consistent short-term improvement in acoustic and perceptual metrics but limited histologic data beyond 9-12 months. Available human biopsy findings reveal fibroblast infiltration and partial ECM integration (eg, silk-hyaluronic acid hydrogels, adipose-derived stromal vascular fraction therapy), yet lack quantitative analysis of collagen I/III ratios, elastin content, and viscoelastic restoration. Professional singers remain largely excluded from histologic or biomechanical cohorts. Persistent racial and geographic disparities further limit access to specialized voice-preservation surgery and longitudinal follow-up. Long-term remodeling after minimally invasive voice-preservation procedures remains underexplored, with crucial gaps in linking tissue biomechanics to clinical outcomes and health equity. This review identifies priorities for multicenter, demographically inclusive research integrating molecular, histologic, and performance-based endpoints to advance equitable, evidence-based voice care for professional singers and high-demand voice users.